Navigation Links
ACTOplus met® XR (pioglitazone HCl and metformin HCl extended-release) Now Available in Pharmacies Nationwide
Date:6/21/2010

DEERFIELD, Ill., June 21 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. announced today that ACTOplus met® XR, an extended-release version of the combination medication ACTOplus met® (pioglitazone HCl and metformin HCl), is now available in United States (U.S.) pharmacies for the treatment of type 2 diabetes as an adjunct to diet and exercise. This once-daily prescription medication, available in two commonly used dosages of pioglitazone and metformin XR – 15 mg/1000 mg and 30 mg/1000 mg tablets – is the first and only oral antidiabetic fixed-dose combination medication with the extended-release formulation of metformin.

ACTOplus met XR combines ACTOS® (pioglitazone HCL) and metformin, two widely used diabetes medications with established safety profiles, in a single tablet. ACTOS directly targets insulin resistance, a condition in which the body does not efficiently use the insulin it produces, and metformin acts primarily by reducing the amount of glucose produced in the liver. These medications work in combination, along with diet and exercise, to help patients with type 2 diabetes improve glycemic control.

Takeda is the inventor and developer of ACTOS, which was launched commercially in the U.S. in 1999. ACTOS has been an effective and appropriate treatment for people living with type 2 diabetes, and has been prescribed for more than 10 million patients to date.

Extended-release metformin, one of the active ingredients in ACTOplus met XR, was developed by Watson Laboratories, a subsidiary of Watson Pharmaceuticals, Inc. and licensed to Takeda Pharmaceutical Company Limited.

ACTOplus met® (pioglitazone HCl and metformin HCl) <
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New Data Showed Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions when Treated with ACTOplus met(R) (pioglitazone HCl and metformin HCl) as Initial Therapy Compared to Either Component Alone
2. Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S.
3. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
4. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
5. New Data Showed ACTOS(R) (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes
6. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
7. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
8. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
9. Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated
10. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
11. Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014  Lockton Dunning Benefits, the ... Companies, announced the addition of Vice President ... Lockton Dunning,s Pharmacy Consulting team, Excelsior Solutions. ... industry experience to the position.  Most recently, she ... at Diplomat Specialty Pharmacy, where she has held ...
(Date:12/24/2014)... RALEIGH, N.C. , Dec. 23, 2014 /PRNewswire/ ... (NASDAQ: ENDP ) (TSX: ENL), and BioDelivery ... today that they have submitted a New Drug Application ... Food and Drug Administration (FDA).  Buprenorphine HCl Buccal Film ... enough to require daily, around-the-clock, long-term opioid treatment and ...
(Date:12/22/2014)... Dec. 22, 2014 Apnea Sciences ( www.apneasciences.com ... in Aliso Viejo , California.  ... the tremendous growth and worldwide expansion, a new facility ... SnoreRx, the anti snore cure have exceeded our expectations ... "We are now in 23 countries and will be ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... 2010 Segal McCambridge Singer & Mahoney, Ltd. and ... in favor of medical device manufacturer I-Flow Corporation.  A ... the District of Oregon returned defense verdicts on all ... three plaintiffs whose cases had been consolidated for trial. ...
... Inc. (Nasdaq: SGMO ) announced today that Edward ... the progress of Sangamo,s ZFP Therapeutic® development programs and an ... on Tuesday, November 16, 2010, at the Lazard Capital Markets ... York City. A live webcast of the presentation ...
Cached Medicine Technology:Sangamo BioSciences Announces Presentation at Lazard Capital Markets Healthcare Conference 2
(Date:12/25/2014)... December 26, 2014 The microscopy ... of 7.2% to reach $5,756.0 million by 2019. ... microscopy market. The electron microscopes product segment is ... forecast period. , Rising focus on nanotechnology, technological ... of the microscopy market. , Get Full Copy ...
(Date:12/25/2014)... 26, 2014 The click ... beauty, strength and durability. Today, the business announces ... is valid until Jan. 30, 2015. , Click ... traditional hardwood. BambooFlooringChina.com is a well-known brand in ... worldwide to find a reliable bamboo flooring supplier. ...
(Date:12/25/2014)... 2014 The report “TS-1 (Colorectal Cancer) ... the current treatment landscape, unmet needs, current pipeline and ... an anti-cancer drug which is typically used for treating ... used for treating gastric cancer and pancreatic cancer. TS-1 ... drug was first approved in 1999 in Japan for ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 “Every three months ... market changes. A-line sweetheart evening dress will be one of ... sales manager of Yunx.co.uk says. Today, the company releases 26 ... discounts, up to 80% off. , “We are trying ... unique style with our latest designs. Along with affordable prices, ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 Recently, Dylan ... dresses, has excitedly released its collection of discounted prom ... to Percy, a senior spokesman of the company, the ... of this promotion is to expand the UK market. ... in several different colors, lengths, and styles: A-line strapless, ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2
... Sky One,Medical, Inc. ("China Sky One Medical" or ... fully integrated pharmaceutical company producing over-the-counter,drugs in the ... it,successfully obtained the production approval from the State ... additional drugs: Sodium Cromoglicate,Eye Drops for the treatment ...
... Re Ltd., the reinsurance unit of White Mountains Insurance Group, Ltd. ... Financial Officer, will retire from full-time work at the end of ... advisor to White Mountains. , , ... the last 7 years Chuck has filled many roles within our ...
... PITTSBURGH, Dec. 16 MED3OOO, Inc., a national healthcare management, ... able to help the City of Newark, Ohio recover lost ... companies. , , After partnering ... of Newark Division Fire & EMS department is now able ...
... Dec. 16 CeloNova BioSciences, Inc., announced,today that ... U.S. Food and,Drug Administration (FDA) for Embozene(TM) Color-Advanced ... tumors (tumors with a,large number of blood vessels ... circulatory system). U.S. commercial sales of,Embozene(TM) Microspheres will ...
... Dec. 16 While all cosmetic surgery,can be performed ... feel or remember their surgery - a condition commonly ... (Photo: http://www.newscom.com/cgi-bin/prnh/20081216/LATU002 ) , ... iv sedation, pioneered by anesthesiologist Dr. Barry L.,Friedberg, is ...
... more efficiently, Fresho.com offers bulk job posting and announces new job ad ... ... NY (PRWEB) December 16, 2008 -- In order to help employers fill ... search engine Fresho.com now offers employers to submit their job openings ...
Cached Medicine News:Health News:China Sky One Medical, Inc. Obtains Production Rights for Two Additional Drugs 2Health News:China Sky One Medical, Inc. Obtains Production Rights for Two Additional Drugs 3Health News:White Mountains Re Announces Management Changes -- Chokel to Retire and Remain Risk Advisor at WTM 2Health News:White Mountains Re Announces Management Changes -- Chokel to Retire and Remain Risk Advisor at WTM 3Health News:White Mountains Re Announces Management Changes -- Chokel to Retire and Remain Risk Advisor at WTM 4Health News:City of Newark, Ohio Increases Safety Services with EMS Revenue Recovered by MED3OOO EMS Billing 2Health News:City of Newark, Ohio Increases Safety Services with EMS Revenue Recovered by MED3OOO EMS Billing 3Health News:CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform 2Health News:CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform 3Health News:CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform 4Health News:Cosmetic Surgery -'Goldilocks' Anesthesia Is Not Mickey Mouse 2Health News:Fresho.Com Offers Efficient Job Postings for Employers and Recruiters 2
... Performance ,MARS Technology is the next generation ... an addition to our current family of ... advantage of new technological breakthroughs in signal ... pulse signal resulting in superior performance during ...
The NPB-40 Handheld Pulse Oximeter is both compact and affordable. It is simple to operate, provides spot-check monitoring of SpO 2 and pulse rate, and is compact enough to fit in your pocket....
... The Nellcor N-20PA Handheld Pulse Oximeter is ... The durable construction of the N-20PA has ... temperatures and conditions it has even ... is conveniently portable for spot check measurements ...
... Nellcor's most popular handheld oximeter has been ... platform and is now compatible with the ... the MAX-FAST Forehead Sensor and SoftCare Nonadhesive ... Oximeter also incorporates Nellcor's latest advanced signal ...
Medicine Products: